Ann: Prospectus, page-104

I'd have to agree they are tremendously valued compared to their counterparts like CAN. CAN trades at a $230M market cap with no notable revenues. HHI boasted a $6.5M FY 20 revenue figure with gross profit of $1.4M. As others have highlighted this is before they ramp up some quite large sales channels. They've got the distribution and products in place with sales to validate it. It's just about executing the rollout now. I think this could be a similar opportunity to RAC or EMV. Have been in both since 2009 and they're my best performers. Up 20X.